logo
  • About Us
    • Who We Are
    • Leadership Team
    • Our Story
    • Awards & Recognitions
    • Patents
    • Contact Us
  • Science & Pipeline
    • The Science of RNAi
    • Pipeline
      • Oncology
      • Fibrosis
      • Medical Aesthetic
      • Antiviral
      • GalAhead™
      • PDoV-GalNAc
    • Research & Development
    • Clinical Studies
    • Clinical Manufacturing
  • Investor Relations
    • Information Disclosure
      • Announcements & Circulars
      • Financial Reports
      • Listing Documents
      • ESG Reports
    • Corporate Governance
    • Events & Presentations
    • Stock Information
    • Analyst Coverage
    • Investor Enquiries
  • Partnership
    • Business Development
    • Our Partners
  • News
    • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Sirnaomics In The News
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • news
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Sirnaomics Ltd. Listed on Main Board of HKEX
      • Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors
      • Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)
      • Sirnaomics Announces Interim Data from Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
      • Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress
      • RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines
      • Sirnaomics Doses First Subject in Phase I Clinical Trial of STP707 for the Treatment of Liver Fibrosis in Primary Sclerosing Cholangitis
      • Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead™ Programs at the TIDES USA 2022  
      • Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit
      • Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment
      • Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology
      • Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics based on its Proprietary GalAhead™ Program at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium
      • Sirnaomics Receives IND Clearance from the Taiwan Ministry of Health and Welfare for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment
      • Sirnaomics Develops Peptide Docking Vehicle (PDoV™) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics
      • Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ
      • Sirnaomics becoming a Constituent of Hang Seng Family of Indexes
      • Sirnaomics' 2022 interim results presentation will be held on 31 August 2022
      • Sirnaomics Advances GalAhead™-Based RNAi Therapeutics for Treatment of Complement-Related Diseases
      • Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
      • Sirnaomics to Present at 3rd Annual Jefferies Asia Forum
      • Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead™ Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference
      • Sirnaomics to Present Latest Developments on GalAhead™ Therapeutic Platform at Upcoming Industry Conferences
      • Sirnaomics Doses the First Patient in Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Aesthetics Treatment
      • Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022
      • Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma In Situ
      • Sirnaomics Announces Interim Data from Phase I Clinical Trial of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors
      • Sirnaomics Marks 15th Anniversary with Opening of New US Headquarters and Laboratories in Germantown, Maryland
      • Sirnaomics Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin Cancers
      • RNAimmune mRNA Cancer Vaccine Program Accepted for Oral Presentation at the 2023 AACR Annual Meeting
      • Sirnaomics to Present Latest Developments in Polypeptide Nanoparticle Platform at the 4th Annual RNAi-Based Therapeutics Summit
      • Sirnaomics' 2022 annual results presentation will be held on 29 March 2023
    • Sirnaomics in the News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • After a $50M IPO, Sirnaomics aims to market the first RNAi drug for oncology
      • Shortly after its latest mega-round, Sirnaomics CEO Patrick Lu says it's time to go public
      • Sirnaomics Advances GalAhead-Based Drug Candidates Focused on Complement-Related Diseases
      • Sirnaomics Testing STP144G Therapy With Eye Toward Human Trials Next Year
      • Exclusive: Sirnaomics hopes to develop non-melanoma skin cancer therapy with its siRNA
      • MoCo biopharma Sirnaomics more than triples footprint with new HQ
    • Media Outreach
  • Careers
    • Working at Sirnaomics
    • Join Us
EN 简 繁
img img img
  • About Us
    • Who We Are
    • Leadership Team
    • Our Story
    • Awards & Recognitions
    • Patents
    • Contact Us
  • Science & Pipeline
    • The Science of RNAi
    • Pipeline
      • Oncology
      • Fibrosis
      • Medical Aesthetic
      • Antiviral
      • GalAhead™
      • PDoV-GalNAc
    • Research & Development
    • Clinical Studies
    • Clinical Manufacturing
  • Investor Relations
    • Information Disclosure
      • Announcements & Circulars
      • Financial Reports
      • Listing Documents
      • ESG Reports
    • Corporate Governance
    • Events & Presentations
    • Stock Information
    • Analyst Coverage
    • Investor Enquiries
  • Partnership
    • Business Development
    • Our Partners
  • News
    • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Sirnaomics In The News
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • news
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Sirnaomics Ltd. Listed on Main Board of HKEX
      • Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors
      • Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)
      • Sirnaomics Announces Interim Data from Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
      • Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress
      • RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines
      • Sirnaomics Doses First Subject in Phase I Clinical Trial of STP707 for the Treatment of Liver Fibrosis in Primary Sclerosing Cholangitis
      • Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead™ Programs at the TIDES USA 2022  
      • Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit
      • Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment
      • Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology
      • Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics based on its Proprietary GalAhead™ Program at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium
      • Sirnaomics Receives IND Clearance from the Taiwan Ministry of Health and Welfare for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment
      • Sirnaomics Develops Peptide Docking Vehicle (PDoV™) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics
      • Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ
      • Sirnaomics becoming a Constituent of Hang Seng Family of Indexes
      • Sirnaomics' 2022 interim results presentation will be held on 31 August 2022
      • Sirnaomics Advances GalAhead™-Based RNAi Therapeutics for Treatment of Complement-Related Diseases
      • Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
      • Sirnaomics to Present at 3rd Annual Jefferies Asia Forum
      • Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead™ Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference
      • Sirnaomics to Present Latest Developments on GalAhead™ Therapeutic Platform at Upcoming Industry Conferences
      • Sirnaomics Doses the First Patient in Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Aesthetics Treatment
      • Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022
      • Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma In Situ
      • Sirnaomics Announces Interim Data from Phase I Clinical Trial of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors
      • Sirnaomics Marks 15th Anniversary with Opening of New US Headquarters and Laboratories in Germantown, Maryland
      • Sirnaomics Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin Cancers
      • RNAimmune mRNA Cancer Vaccine Program Accepted for Oral Presentation at the 2023 AACR Annual Meeting
      • Sirnaomics to Present Latest Developments in Polypeptide Nanoparticle Platform at the 4th Annual RNAi-Based Therapeutics Summit
      • Sirnaomics' 2022 annual results presentation will be held on 29 March 2023
    • Sirnaomics in the News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • After a $50M IPO, Sirnaomics aims to market the first RNAi drug for oncology
      • Shortly after its latest mega-round, Sirnaomics CEO Patrick Lu says it's time to go public
      • Sirnaomics Advances GalAhead-Based Drug Candidates Focused on Complement-Related Diseases
      • Sirnaomics Testing STP144G Therapy With Eye Toward Human Trials Next Year
      • Exclusive: Sirnaomics hopes to develop non-melanoma skin cancer therapy with its siRNA
      • MoCo biopharma Sirnaomics more than triples footprint with new HQ
    • Media Outreach
  • Careers
    • Working at Sirnaomics
    • Join Us
QR
  • Announcements & Circulars
  • Financial Reports
  • Listing Documents
  • ESG Reports

N/A

N/A

N/A

Sirnaomics Ltd. 2021 Annual Report

2022.04.27

Sirnaomics Ltd. 2022 Interim Report

2022.09.22

N/A

N/A

N/A

GLOBAL OFFERING - [Formal Notice]

GLOBAL OFFERING - [Offer for Subscription]

GLOBAL OFFERING

GREEN APPLICATION FORM

N/A

N/A

N/A

Sirnaomics Ltd. 2021 Annual Report

Sirnaomics Ltd. 2021 Annual Report

2022.04.27

Sirnaomics Ltd. 2021 Annual Report
logo
Sirnaomics Ltd.

20511 Seneca Meadows Parkway, Suite 200 Germantown, MD 20876, USA

© 2007-2022 by Sirnaomics
  • About Us
    • Who We Are
    • Leadership Team
    • Our Story
    • Awards & Recognitions
    • Patents
    • Contact Us
  • Science & Pipeline
    • The Science of RNAi
    • Pipeline
      • Oncology
      • Fibrosis
      • Medical Aesthetic
      • Antiviral
      • GalAhead™
      • PDoV-GalNAc
    • Research & Development
    • Clinical Studies
    • Clinical Manufacturing
  • Investor Relations
    • Information Disclosure
      • Announcements & Circulars
      • Financial Reports
      • Listing Documents
      • ESG Reports
    • Corporate Governance
    • Events & Presentations
    • Stock Information
    • Analyst Coverage
    • Investor Enquiries
  • Partnership
    • Business Development
    • Our Partners
  • News
    • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Sirnaomics In The News
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • news
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Sirnaomics Ltd. Listed on Main Board of HKEX
      • Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors
      • Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)
      • Sirnaomics Announces Interim Data from Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
      • Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress
      • RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines
      • Sirnaomics Doses First Subject in Phase I Clinical Trial of STP707 for the Treatment of Liver Fibrosis in Primary Sclerosing Cholangitis
      • Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead™ Programs at the TIDES USA 2022  
      • Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit
      • Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment
      • Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology
      • Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics based on its Proprietary GalAhead™ Program at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium
      • Sirnaomics Receives IND Clearance from the Taiwan Ministry of Health and Welfare for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment
      • Sirnaomics Develops Peptide Docking Vehicle (PDoV™) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics
      • Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ
      • Sirnaomics becoming a Constituent of Hang Seng Family of Indexes
      • Sirnaomics' 2022 interim results presentation will be held on 31 August 2022
      • Sirnaomics Advances GalAhead™-Based RNAi Therapeutics for Treatment of Complement-Related Diseases
      • Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
      • Sirnaomics to Present at 3rd Annual Jefferies Asia Forum
      • Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead™ Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference
      • Sirnaomics to Present Latest Developments on GalAhead™ Therapeutic Platform at Upcoming Industry Conferences
      • Sirnaomics Doses the First Patient in Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Aesthetics Treatment
      • Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022
      • Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma In Situ
      • Sirnaomics Announces Interim Data from Phase I Clinical Trial of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors
      • Sirnaomics Marks 15th Anniversary with Opening of New US Headquarters and Laboratories in Germantown, Maryland
      • Sirnaomics Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin Cancers
      • RNAimmune mRNA Cancer Vaccine Program Accepted for Oral Presentation at the 2023 AACR Annual Meeting
      • Sirnaomics to Present Latest Developments in Polypeptide Nanoparticle Platform at the 4th Annual RNAi-Based Therapeutics Summit
      • Sirnaomics' 2022 annual results presentation will be held on 29 March 2023
    • Sirnaomics in the News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • After a $50M IPO, Sirnaomics aims to market the first RNAi drug for oncology
      • Shortly after its latest mega-round, Sirnaomics CEO Patrick Lu says it's time to go public
      • Sirnaomics Advances GalAhead-Based Drug Candidates Focused on Complement-Related Diseases
      • Sirnaomics Testing STP144G Therapy With Eye Toward Human Trials Next Year
      • Exclusive: Sirnaomics hopes to develop non-melanoma skin cancer therapy with its siRNA
      • MoCo biopharma Sirnaomics more than triples footprint with new HQ
    • Media Outreach
  • Careers
    • Working at Sirnaomics
    • Join Us